{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 30,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 20,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/12",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.62,
        "w": 0.82,
        "x": 0.12,
        "y": 0.24
      },
      "kind": "chart",
      "text": "Bar chart showing PE Scale (0-100) for various participants (P1-P18) across four dose groups (2mg, 6mg, 12mg, 18mg), with a PE Threshold at 75 and average lines for each dose group.",
      "attrs": {
        "x_axis_label": "Participant ID and Dose Group",
        "y_axis_label": "PE Scale"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "add88fc0-919d-4378-a8b1-9b553e6bf37d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.16,
        "x": 0.81,
        "y": 0.04
      },
      "kind": "image",
      "text": "GH Research",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68aaef81-391e-47d3-bf63-a7be94dbab70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.01,
        "y": 0.78
      },
      "kind": "legend",
      "text": "Average for dose group",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f04c807-a786-4076-a23d-832448fd10e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.09,
        "x": 0.02,
        "y": 0.34
      },
      "kind": "legend",
      "text": "PE Threshold",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "362f1dfb-8f22-444e-9148-c031377aa924",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.02,
        "x": 0.95,
        "y": 0.95
      },
      "kind": "other",
      "text": "12",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e71ffacd-4cf4-4ef1-a241-1d8611a7b85f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.08,
        "x": 0.06,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "PE, Peak Experience",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "249428cb-c8df-4079-ba95-6e636d95d8b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "2023© GH Research PLC",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c7ea672-77b2-4148-ba2b-fb2923faebdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.79,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Part A – Peak Experience (PE) Dose-Effects and Inter-Person Variability",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1b14d42-9cc7-4000-9d7e-ebe2fcf70683",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "489c49ab-9317-4529-845f-38f6910d33d3",
      "evidence": "Bar chart showing PE Scale (0-100) for various participants (P1-P18) across four dose groups (2mg, 6mg, 12mg, 18mg)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}